Status:
UNKNOWN
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Cocaine Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
2.1. General To evaluate the efficacy and safety of a Cannabis sativa extract (CBD (Cannabidiol) + up to 0.3% THC (Delta-9-tetrahydrocannabinol)), compared to placebo, in the treatment of cocaine/crac...
Detailed Description
The project is being developed at the Interdisciplinary Group for Alcohol and Drug Studies (GREA). GREA is a service of the Perdizes Institute - Department of Psychiatry of the Hospital das Clínicas o...
Eligibility Criteria
Inclusion
- Patients over 18 years old Patients who meet the DSM-5 criteria for Cocaine use disorder.
Exclusion
- Patients diagnosed with Schizophrenia and Bipolar Affective Disorder Patients with a history of severe head trauma Patients who used marijuana in the last month Patients who meet the criteria for other substances dependence besides crack/cocaine and tobacco.
Key Trial Info
Start Date :
October 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 23 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06159387
Start Date
October 23 2023
End Date
October 23 2025
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Perdizes
São Paulo, São Paulo, Brazil, 05021-001,